Pfizer Japan Obtains Approval for ZYVOX, Detrusitol, J Zoloft in Japan.

Tokyo, Japan, Apr 24, 2006 - (JCN) - Pfizer Japan announced on April 24 that it received approval for an additional indication for ZYVOX Tablets 600mg/ ZYVOX Injection 600mg, its proprietary antibacterial agent, from the Ministry of Health, Labor and Welfare.

ZYVOX is now available for the treatment of infections associated with MRSA (methicillin-resistant Staphylococcus aureus). ZYVOX (linezolid), which has been marketed in Japan since 2001, is currently used in the treatment of infections associated with vancomycin-resistant Enterococcus (VRE).

Pfizer Japan also announced that it received approval for Detrusitol Capsule 2mg/4mg, its proprietary agent for treating overactive bladder (OAB), and J ZOLOFT Tablets 25mg/50mg, its proprietary antidepressant, on the same day.

A selective anticholinergic agent developed by Pfizer of the US, Detrusitol can exert beneficial effects with once-a-day dosage. Initially launched in 1997, the agent is currently prescribed to 10 million patients in about 80 countries worldwide.

J ZOLOFT (sertraline hydrochloride), a selective seretonin reuptke inhibitor developed by Pfizer of the US, is the most prescribed drug for the treatment of depression in the world.

It is estimated that about 12 million people suffer from depression in Japan.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.